Research programme: controlled-release ophthalmic therapeutics - EyeGate Pharma

Drug Profile

Research programme: controlled-release ophthalmic therapeutics - EyeGate Pharma

Alternative Names: CMHA-S films - EyeGate Pharma; Controlled-release antibacterial ophthalmic therapeutics - EyeGate Pharma; JDE 001; JDE-004; JDE-005; JDE-006; Recombinant hGH - EyeGate Pharma; Recombinant human growth hormone - EyeGate Pharma; Somatropin - EyeGate Pharma

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jade Therapeutics
  • Developer EyeGate Pharma
  • Class Antibacterials; Eye disorder therapies; Growth hormones
  • Mechanism of Action Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Corneal disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Corneal disorders; Corneal injuries; Dry eyes; Infectious keratitis

Most Recent Events

  • 13 Sep 2016 Jade Therapeutics receives a second year of SBIR grant from the US Army Medical Research and Materiel Command for controlled-release opthalmic therapeutics development in corneal injuries
  • 01 Aug 2016 Preclinical development is ongoing in USA
  • 07 Mar 2016 Jade Therapeutics has been acquired by EyeGate Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top